Royal Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History

Royal Bank of Canada’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.51M	Buy	+15,000	New	+$4.52M	﹤0.01%	2689
2024 Q2	–	Sell	-100	Closed	-$15K	–	6994
2024 Q1	$15K	Buy	+100	New	+$16.7K	﹤0.01%	6023
2021 Q1	–	Sell	-60,000	Closed	-$7.8M	–	7392
2020 Q4	$7.8M	Hold	60,000	–	–	﹤0.01%	1895
2020 Q3	$8.74M	Hold	60,000	–	–	﹤0.01%	1631
2020 Q2	$8.89M	Hold	60,000	–	–	﹤0.01%	1568
2020 Q1	$6.53M	Hold	60,000	–	–	﹤0.01%	1631
2019 Q4	$6.91M	Hold	60,000	–	–	﹤0.01%	1904
2019 Q3	$4.83M	Hold	60,000	–	–	﹤0.01%	2115
2019 Q2	$4.35M	Buy	+60,000	New	+$4.6M	﹤0.01%	2177

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's ALNY Position: Q2 2026 in Review

Royal Bank of Canada increased its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, buying an estimated $25.4M and bringing the position to 875,859 shares worth $264M. The position accounts for 0.04% of the portfolio, ranked #382.

Royal Bank of Canada first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Royal Bank of Canada held 875,859 shares of Alnylam Pharmaceuticals worth $264M as of Q2 2026.
Royal Bank of Canada bought 84,344 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $25.4M.
Alnylam Pharmaceuticals made up 0.04% of Royal Bank of Canada's portfolio in Q2 2026, its #382 holding.
Royal Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.